MedPath

Clinical trial for safety and efficacy of grassroots leads in the management of Osteopenia / Osteoporosis among postmenopausal women.

Phase 2
Conditions
Health Condition 1: M810- Age-related osteoporosis without current pathological fracture
Registration Number
CTRI/2019/06/019792
Lead Sponsor
ational innovation foundation
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Postmenopausal women, defined as no menstruation for the last 12 months.

2. B.M.D.T. Score -1 to -3.5 at hip, spine and forearm (worst score at any of

the three sites to be considered)

Exclusion Criteria

1. B.M.D. T. score above -1 and less than -3.5

2. All women who are consuming any drug which is known to affect bone metabolism in doses for e.g. SERMs, bisphophonates, calcitonin, Vit. D more than 60,000 units and corticosteroids more than 5mg/day for more than 3 months, methotrexate, anticonvulsants and diuretics.

3. Patients suffering from congenital disorders (Dysosteogenesis and Marfan.s Syndrome)

4. Patients with endocrine disorders (Hyperthyroidism, hyperparathyroidism, Untreated Cushing.s syndrome)

5. Patients with evidence of malignancy

6. Patients suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Epilepsy)

7. Patients suffering from chronic hepatic disorder, renal failure or cardiac dysfunction.

8. Patient suffering from uncontrolled DM-2 or uncontrolled hypertension.

8. Patients suffering from Osteomalacia.

9. Patients suffering from Malabsorption syndrome

10. Patients undergone Organ transplantation or on immunosuppressive therapy

11. Prolonged immobilization

12. Patients whose Serum Ca++ level < 2.2 or > 2.6 mmol/L ( < 9 or >10.5 mg/dL)

13. History of renal stones

14. Long bone fracture in last 6 months.

15. Patient not ready to give an informed consent

16. Subjects who has participated in any other clinical study in last 30 days.

17. Patients with clinical evidence of active and chronic illness as rheumatoid arthritis, gout,SLE, Psoriatic arthritis.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To compare the safety and efficacy of Grassroots leads with Ayurvedic drug (Lakshadi Guggulu and Praval Pishti) and Allopathic drug(Shalcal) in subject with postmenopausal osteoporosis.Timepoint: 1 year
Secondary Outcome Measures
NameTimeMethod
Mean changes in quality of life among women suffering from postmenopausal osteoporosisTimepoint: 1 year;To assess the biomarker response for bone formation of study drugs in postmenopausal osteoporosis <br/ ><br>Timepoint: 1 year
© Copyright 2025. All Rights Reserved by MedPath